Isolation and characterization of β-transducin repeat-containing protein ligands screened using a high-throughput screening system
Related Experiment Video
Updated: Aug 18, 2026
Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
Xintong Liu1,2,3, Emiko Sanada1,3,4, Jiang Li5
1Chemical Resource Development Research Unit, RIKEN CSRS, Wako, Saitama, 351-0198, Japan.
Abstract:
β-transducin repeat-containing protein (β-TrCP) is an F-box protein subunit of the E3 Skp1-Cullin-F box (SCF) type ubiquitin-ligase complex, and provides the substrate specificity for the ligase. To find potent ligands of β-TrCP useful for the proteolysis targeting chimera (PROTAC) system using β-TrCP in the future, we developed a high-throughput screening system for small molecule β-TrCP ligands. We screened the chemical library utilizing the system and obtained several hit compounds. The effects of the hit compounds on in vitro ubiquitination activity of SCFβ-TrCP1 and on downstream signaling pathways were examined. Hit compounds NPD5943, NPL62020-01, and NPL42040-01 inhibited the TNFα-induced degradation of IκBα and its phosphorylated form. Hence, they inhibited the activation of the transcription activity of NF-κB, indicating the effective inhibition of β-TrCP by the hit compounds in cells. Next, we performed an in silico analysis of the hit compounds to determine the important moieties of the hit compounds. Carboxyl groups of NPL62020-01 and NPL42040-01 and hydroxyl groups of NPD5943 created hydrogen bonds with β-TrCP similar to those created by intrinsic target phosphopeptides of β-TrCP. Our findings enhance our knowledge of useful small molecule ligands of β-TrCP and the importance of residues that can be ligands of β-TrCP.
Insights
Researchers developed a high-throughput screening system to identify small molecule ligands for β-transducin repeat-containing protein (β-TrCP). Several compounds were found to inhibit β-TrCP activity in cells, impacting NF-κB signaling.
Area of Science:
- Biochemistry and Molecular Biology
- Drug Discovery and Development
Background:
- β-transducin repeat-containing protein (β-TrCP) is a crucial component of the SCF E3 ubiquitin ligase complex, dictating substrate specificity.
- Targeting β-TrCP is of interest for developing novel therapeutic strategies, including proteolysis targeting chimeras (PROTACs).
Purpose of the Study:
- To develop a high-throughput screening (HTS) system for identifying small molecule ligands of β-TrCP.
- To discover potent β-TrCP ligands for potential future application in PROTAC technology.
- To investigate the mechanism of action and key structural features of identified β-TrCP inhibitors.
Main Methods:
- Development and implementation of an HTS system to screen a chemical library for β-TrCP ligands.
- In vitro assessment of hit compounds' effects on SCFβ-TrCP1 ubiquitination activity.
- Evaluation of hit compounds' impact on TNFα-induced IκBα degradation and NF-κB transcriptional activity in cells.
- In silico analysis to identify key functional groups responsible for β-TrCP binding.
Main Results:
- Several hit compounds, including NPD5943, NPL62020-01, and NPL42040-01, were identified.
- These compounds effectively inhibited the TNFα-induced degradation of IκBα and its phosphorylated form, thereby suppressing NF-κB activation.
- In silico analysis revealed that carboxyl and hydroxyl groups in the hit compounds form hydrogen bonds with β-TrCP, mimicking interactions with natural phosphopeptide substrates.
Conclusions:
- The study successfully established an HTS system for discovering β-TrCP ligands.
- Identified small molecules demonstrate potent inhibition of β-TrCP activity in cellular contexts.
- The findings provide valuable insights into the structural requirements for β-TrCP ligand design, crucial for PROTAC development.
